Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Gavilast Heartburn and Indigestion 75mg Film-coated tablets

Active Ingredient:
ranitidine hydrochloride
Reckitt Benckiser Healthcare (UK) Ltd See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 03 Aug 2017
1. Name of the medicinal product

Ranitidine 75 mg film-coated tablets

Gavilast Heartburn and Indigestion 75mg Film-coated tablets

2. Qualitative and quantitative composition

Each tablet contains ranitidine 75 mg (as the hydrochloride).

For excipients, see 6.1.

3. Pharmaceutical form

Film-coated tablets.

White coloured, round, biconvex film coated tablets with k logo on one face and 75 on the other.

4. Clinical particulars
4.1 Therapeutic indications

Symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity.

4.2 Posology and method of administration

Route of Administration



Adults (Including the Elderly) and children 16 years of age and older:

Swallow one Ranitidine 75 mg film-coated tablet whole, with a drink of water, as soon as you have symptoms. If symptoms persist for more than one hour or return, take another tablet.

Do not take more than two tablets in 24 hours.

Do not take the tablets for more than 6 days without the advice of a pharmacist or doctor.

Children under 16 years

Not recommended for children under 16 years of age

4.3 Contraindications

Ranitidine is contraindicated for people known to be hypersensitive to the drug or any ingredients of Ranitidine 75mg Film-coated tablets.

4.4 Special warnings and precautions for use

Treatment with a histamine H2-antagonist such as ranitidine may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition.

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment. Ranitidine 75 mg film-coated tablet is not suitable for these patients without medical supervision

People taking non-steroidal anti-inflammatory drugs, especially those with a history of peptic ulcer and the elderly should not self-medicate with Ranitidine 75 mg film-coated tablet but seek their doctor's advice before use.

People with a history of porphyria should avoid use of the product.

Consumers will be advised not to purchase a second pack of tablets without the advice of a pharmacist of doctor.

The product is not indicated in the following people without seeking their doctor's advice:

• Patients with severe renal and/or hepatic impairment.

• Patients under regular medical supervision for other reasons.

• Patients taking medications either physician prescribed or self prescribed.

• Those with difficulty swallowing, persistent stomach pain or unintended weight loss in association with symptoms of indigestion.

• Those who are middle-aged or elderly with new or recently changed symptoms of indigestion.

In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia.

A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.82 (95% CI, 1.26–2.64).

4.5 Interaction with other medicinal products and other forms of interaction

Ranitidine has the potential to affect the absorption, metabolism or renal excretion of other drugs. The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment.

Interactions occur by several mechanisms including:

1) Inhibition of cytochrome P450-linked mixed function oxygenase system:

Ranitidine at usual therapeutics doses does not potentiate the actions of drugs which are inactivated by this enzyme systems such as diazepam, lidocaine, phenytoin, propranol and theophylline.

There have been reports of altered prothrombin time with coumarin anticoagulants (e.g. warfarin). Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine.

2) Alteration of gastric pH:

The bioavailability of certain drugs may be affected. This can result in either an increase in absorption or a decrease in absorption.

4.6 Fertility, pregnancy and lactation

Ranitidine crosses the placenta but therapeutic doses administered to obstetric patients in labour or undergoing caesarean section have been without any adverse effect on labour, delivery or subsequent neonatal progress.

Like other over the counter drugs it should not be taken during pregnancy without consulting a doctor or pharmacist. It is also excreted in human breast milk and women who are breast-feeding will be advised to speak to their doctor before taking Ranitidine tablets.

4.7 Effects on ability to drive and use machines

No known effect. However, when driving vehicles or operating machinery it must be borne in mind that dizziness or drowsiness, confusion and a blurred vision may occasionally occur when taking Ranitidine Tablets

4.8 Undesirable effects

The following convention has been utilised for the classification of undesirable effects: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000), very rare (1/10,000).

Adverse event frequencies have been estimated from spontaneous reports from post-marketing data.

Hepatobiliary Disorders

Rare: Transient and reversible changes in liver function tests.

Very Rare: Hepatitis (hepatocellular, hepatocanalicular or mixed) with or without jaundice. These were usually reversible.

Gastrointestinal Disorders

Very Rare: Acute pancreatitis and diarrhoea.

Uncommon: Abdominal pain, constipation, nausea. (these symptoms mostly improved during continued treatment).

Blood & Lymphatic System Disorders

Very rare: Blood count changes (Leucopenia and thrombocytopenia). These are usually reversible. Agranulocytosis or pancytopenia, sometimes with marrow hypoplasia or aplasia.

Immune System Disorders

Rare: Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension, chest pain)

Very rare: Anaphylactic shock.

These reactions have occasionally occurred after a single dose.

Cardiac Disorders

Very Rare: As with other H2 receptor antagonists bradycardia and A-V block.

Nervous System Disorders

Very rare: Headache (sometimes severe), dizziness and reversible involuntary movement disorders.

Psychiatric Disorders

Very rare: reversible mental confusion, depression and hallucinations

These have been reported, predominantly in severely ill and elderly patients.

Skin and Subcutaneous Tissue Disorders

Rare: Skin rash

Very rare: erythema multiforme and alopecia.

Musculoskeletal and Connective Tissue Disorders

Very rare: Musculoskeletal symptoms such as arthralgia and myalgia

Eye Disorders

Very Rare: Reversible blurred vision.

There have been reports of blurred vision, which is suggestive of a change of accommodation.

Vascular Disorders

Very Rare: Vasculitis

Renal and Urinary Disorders

Very Rare: Acute interstitial nephritis

Rare: Elevation of plasma creatinine (usually slight; normalised during continued treatment)

Reproductive System and Breast Disorders

Very Rare: Reversible impotence. Breast symptoms and conditions (such as gynaecomastia and galactorrhea)

Discontinuation of therapy may be necessary in order to establish the underlying cause.

No clinically significant interference with endocrine or gonadal function has been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at:

4.9 Overdose

Ranitidine is very specific in action and accordingly no particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If need be, the drug may be removed from the plasma by haemodialysis.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion.

Ranitidine has a long duration of action and so a single 75mg dose effectively suppresses gastric acid secretion for twelve hours.

Clinical studies have shown that ranitidine 75 mg can relieve the symptoms of excess acid production for up to twelve hours.

5.2 Pharmacokinetic properties


Following oral administration of 150 mg ranitidine, maximum plasma concentrations (300 to 550 ng/mL) occurred after 1-3 hours. Two distinct peaks or a plateau in the absorption phase result from reabsorption of drug excreted into the intestine. The absolute bioavailability of ranitidine is 50-60%, and plasma concentrations increase proportionally with increasing dose up to 300 mg.

Absorption is not significantly impaired by food or antacids.


Ranitidine is not extensively bound to plasma proteins (15%), but exhibits a large volume of distribution ranging from 96 to 142 L.


Ranitidine is not extensively metabolised. The fraction of the dose recovered as metabolites includes 6% of the dose in urine as the N-Oxide, 2% as the S-Oxide, 2% as desmethyl ranitidine and 1-2% as the furoic acid analogue.


Plasma concentrations decline bi-exponentially, with a terminal half-life of 2-3 hours. The major route of elimination is renal. After IV administration of 150 mg 3H-ranitidine, 98% of the dose was recovered, including 5% in the faeces and 93% in the urine, of which 70% was unchanged parent drug. After oral administration of 150 mg 3H-ranitidine, 96% of the dose was recovered, 26% in the faeces and 70% in urine of which 35% was unchanged parent drug. Less than 3% of the dose is excreted in bile. Renal clearance is approximately 500mL/min, which exceeds glomerular filtration indicating net renal tubular secretion.

Special Patient Populations

• Patients over 50 years of age

In patients over 50 years of age, half-life is prolonged (3-4 h) and clearance is reduced, consistent with the age-related decline of renal function. However, systemic exposure and accumulation are 50% higher. This difference exceeds the effect of declining renal function, and indicates increased bioavailability in older patients.

5.3 Preclinical safety data

Extensive studies have been carried out in animals. The pharmacology of ranitidine hydrochloride shows it to be a surmountable H2 receptor antagonist which produces an inhibition of gastro acid secretion. Extensive toxicological investigators have been conducted which predicted a very safe profile for clinical use. This safety has been confirmed by extensive use in patients for many years.

6. Pharmaceutical particulars
6.1 List of excipients

Microcrystalline cellulose,

Magnesium stearate,


Titanium dioxide.

6.2 Incompatibilities

None known

6.3 Shelf life

36 months.

6.4 Special precautions for storage

Do not store above 25°C.

Store in the original package in order to protect from light.

6.5 Nature and contents of container

Blister of 6 and 12 tablets.

The blisters are made from:

a) Polyamide/Aluminium/PVC lidded with Aluminium

b) PVC/PVDC lidded with Aluminium

6.6 Special precautions for disposal and other handling

Not applicable.

7. Marketing authorisation holder

Noumed Life Sciences Limited

Noumed House

Shoppenhangers Road




United Kingdom

8. Marketing authorisation number(s)

PL 44041/0028

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Reckitt Benckiser Healthcare (UK) Ltd
Company image
RB Consumer Relations, PO Box 4644, SLOUGH, SL1 0NS, UK
0333 2005 345
Medical Information Direct Line
0333 2005 345
Customer Care direct line
0333 2005 345